SCHEMBL29638567

SCHEMBL29638567

Cc1ccc2c(Nc3c(F)c(F)cc(F)c3F)nccc2c1N

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 13/20 0.36
RAF1 P04049 7/20 0.36
CSF1R P07333 5/20 0.36
DDR1 Q08345 5/20 0.36
DDR2 Q16832 5/20 0.36
LCK P06239 6/20 0.35
TEK Q02763 5/20 0.35
KDR P35968 3/20 0.35
ARAF P10398 1/20 0.35
TDO2 P48775 2/20 0.34
IDO1 P14902 2/20 0.34
NOS3 P29474 1/20 0.33
NOS2 P35228 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
GAA P10253 1/20 0.33
HPGD P15428 1/20 0.33
HSD17B10 Q99714 1/20 0.33
HDAC3 O15379 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24399572 0.86 RAPGEF4 (0.40) BRAFRAF1CSF1RDDR1DDR2
SCHEMBL29638582 0.84 BRAF (0.35) BRAFRAF1CSF1RDDR1DDR2
SCHEMBL26210990 0.84 BRAF (0.35) BRAFRAF1CSF1RDDR1DDR2
SCHEMBL29638638 0.84 EGFR (0.36) BRAFRAF1CSF1RDDR1DDR2
SCHEMBL24399714 0.84 EGFR (0.36) BRAFRAF1CSF1RDDR1DDR2
SCHEMBL24399762 0.79 DHFR (0.40) BRAFRAF1CSF1RDDR1DDR2
SCHEMBL24399688 0.79 FGFR1 (0.44) BRAFRAF1KDRALDH1A1GAA
SCHEMBL26210494 0.79 HDAC3 (0.44) BRAFRAF1CSF1RKDRTDO2
SCHEMBL30402598 0.79 ALDH1A1 (0.39) BRAFRAF1CSF1RDDR1DDR2
SCHEMBL25376685 0.79 ALDH1A1 (0.39) BRAFRAF1CSF1RDDR1DDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230312556-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) 2023-10-05 US disclosed
EP-4238967-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) 2023-09-06 EP disclosed
WO-2022089219-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2022-05-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230312556-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF AHR, ARNT, NOTUM BRAF 720/4885RAF1 2075/4885CSF1R 987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.